Picture of Sinopharm logo

1099 — Sinopharm News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareBalancedLarge CapContrarian

Sinopharm rises most in 4 months on deal to sell Merck COVID drug in China

** Shares of Chinese pharmaceutical and medical devices
distributor Sinopharm Group Co Ltd  1099.HK  rise as much as 3%
to HK$16.30, their biggest intraday pct gain since May 20     
    ** Drugmaker Merck & Co  MRK.N  said on Wednesday that it
has agreed to allow Sinopharm to distribute and import its
COVID-19 antiviral molnupiravir in China, if the drug is
approved for use there  urn:newsml:reuters.com:*:nL1N30Z2R6
    ** Merck said it will allow China National Biotec Group, an
affiliate of Sinopharm, to make the drug in China and has agreed
to transfer technology to help with that production
    ** The Hang Seng Commerce & Industry Index  .HSNC  and the
healthcare index  .HSCIH  rise 1.4% each
    ** The Hang Seng Composite Index  .HSCI  climbs 0.9% and the
Hang Seng Index  .HSI  rises 1.2%
    ** As of last close, Sinopharm stock down 6.7% this year
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))

Recent news on Sinopharm

See all news